Marcelo Cartaxo Queiroga; Alvaro Mitsunori Nishikawa; Luciano Morganti Paladini; Pedro Alves Lemos Neto; Fabio Sândoli Brito Júnior; Rogério Sarmento-Leite; Christiane Bueno; Otávio Augusto C. Clark; J. Antonio Marin-Neto; J. Eduardo Sousa
Implante Transcatéter de Bioprótesis Valvular Pulmonar: Revisión Sistemática de la Literatura
Tobias Engel Ayer Botrel, Otávio Augusto C. Clark, Marcelo C. Queiroga, Raul I. Rossi Filho, Carlo B. Pilla, Raul S. Arrieta, Salvador Cristovão, Célia C. Silva, Cesar A. Esteves, Edmundo Clarindo Oliveira, Luiz Carlos Simões, Francisco Chamié, Julia
CoreValve Evolut R CE: Good results at 6 months of the new CoreValve repositionable
This study evaluated the safety and efficacy of the new repositionable self-expanding valve. The primary end point was all-cause mortality and stroke at 30 days. 60 patients were included and the possibility for reposition was used 22 times between 12 recaptures and 10 re-sheathed of the valve. All maneuvers were carried out successfully. A 30...
TAVR é um procedimento tão seguro e eficaz quanto a substituição cirúrgica num seguimento de dois anos em pacientes de menor risco.
Fundamentos e Objetivos: A substituição da válvula aórtica via transcateter (TAVR) é uma opção em determinados pacientes cirúrgicos de alto risco com estenose da válvula aórtica grave. Desconhecemos se a TAVR pode ser introduzida com segurança para os pacientes de baixo risco. O estudo NOTION (Nordic Aortic Valve Intervention Trial) é um ensaio clínico randomizado...
PARTNER cohort B: Clinical events at 3 years follow-up in patients with
Background: Percutaneous aortic valve implantation (TAVI) is the treatment of choice for patients with severe aortic stenosis considered inoperable according to clinical outcomes at 12 months as reported in the PARTNER study, which demonstrated a reduction in mortality and an improvement in the quality of life for patients. However, the long term benefit of this...
PARTNER cohort A at three years, the benefit continues
The PARTNER Cohort A randomized 699 elderly patients, (mean age 84.1), with severe aortic stenosis for TAVI or conventional surgery in 26 centers. The group of patients who received TAVI was divided into two groups: trans-femoral procedure, (244 patients), or trans-apical procedure, (104 patients). After one year mortality was similar but stroke and transient ischemic...
TCT Session
Alan Wilson and Szeto Zajarias show that vascular complications of the trans-femoral path remain an important factor because of the high profile of the catheters used in TAVI and the appearance of smaller devices, as well as the experience of surgeons, will progressively reduce complication rates. Josep Rodes-Cabau commented about the negative impact a stroke...
COREVALVE EXTREME RISK: Promising results with CoreValve in very high-risk patients
Percutaneous aortic valve implantation ( TAVI ) recently demonstrated its superiority over medical treatment in patients with severe aortic stenosis and high surgical risk. Furthermore patients receiving TAVI showed a survival surgery equivalent to one year. This study included 471 patients with symptomatic severe aortic stenosis discarded of surgery due a very high risk. The...
SOLACI relaunches its SOLidario program in Colombia
The Latin American Society of Interventional Cardiology successfully relaunched its SOLidario program, practicing the implantation of an aortic valve catheter (TAVI) in the Instituto de Angiografía de Occidente at Cali. It was during the XXIV SOLACI Conference edition held on October 30 and 31 in Colombia. SOLACI understands the need to develop a social...